Blue Earth Therapeutics Ltd. has expanded its manufacturing agreements with Seibersdorf Labor GmbH to include the manufacture of its investigational 225Ac-based radioligand therapy.

The agreement provides future supply to UK, EU and US clinical trial sites. (225Ac) rhPSMA?10.1, an investigational radiohybrid (rh) Prostate?Specific Membrane Antigen?targeted therapeutic radiopharmaceutical, is the second candidate in Blue Earth Therapeutics’ oncology development program of next-generation therapeutic radiopharmaceuticals.

“We are very pleased to add the manufacture of our 225Ac-based investigational product to our partnership with Seibersdorf Labor,” said David E. Gauden, DPhil., Chief Executive Officer of Blue Earth Therapeutics Ltd.

“It has the potential to be a product of high purity and stability, and this partnership will enable supply of the clinical trial sites in London, and other regions if necessary. Seibersdorf has been an excellent and collaborative partner, and we look forward to working with them on many more projects in the future,” Gauden added.

“This is our first project using the 225Ac radioisotope and we have implemented dedicated infrastructure and services to support it,” said Dr. Markus Neumann, Managing Director of Seibersdorf Labor GmbH.

“We are excited to take on the challenge of developing in-house expertise for 225Ac and expand our projects with Blue Earth Therapeutics to include this new agent and look forward to delivering doses to treat patients in clinical trials. Blue Earth Therapeutics has been a very supportive partner as we expand our capabilities, and we are proud to be part of their network,” he added.